Current:Home > ContactFDA approves a new antibody drug to prevent RSV in babies -AssetBase
FDA approves a new antibody drug to prevent RSV in babies
View
Date:2025-04-18 10:59:55
This fall, for the first time many babies in the U.S. will be able to get a shot to fend off RSV, a respiratory virus that can cause serious lung disease in infants and young children.
The Food and Drug Administration Monday approved nirsevimab, a single shot of antibodies that was shown in clinical trials to lower the need for medical care from RSV for babies by 70-75%.
Respiratory syncytial virus, or RSV is a viral infection that puts between 58,000 to 80,000 young children in the hospital each year, making it the leading cause of hospitalization among infants in the U.S.
"Today's approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system," said Dr. John Farley, director of the Office of Infectious Diseases in the FDA's Center for Drug Evaluation and Research in a statement.
The treatment can be used to protect infants' during their first RSV season. It is also approved to provide protection during a second season for children up to 2 years old and at risk of severe RSV disease.
Drugmakers AstraZeneca and Sanofi plan to start offering the treatment – which will be marketed as Beyfortus – in time for the upcoming RSV season this fall when respiratory viruses spread widely in much of the country.
They have not announced a price for the product, though a spokesperson for Sanofi says it will be similar to a series of HPV vaccines. For comparison, the recommended series of HPV vaccines for young children costs more than $500 on the commercial market.
In June, a panel of advisers to the FDA had recommended that the agency approve the new antibody drug.
There was unanimous support on the 21-person committee for approving the drug's use in infants ahead of or during their first RSV season. And, in a separate vote, all but two members of the panel supported giving the drug to infants with medical risks through their second RSV season. The FDA ultimately approved it for both uses.
"This is one of the most important infectious diseases in the pediatric population," said Dr. Mary Anne Jackson, a pediatrician at Children's Mercy in Kansas City, Missouri and a voting member.
Members of the committee said the data presented by the drugmakers, AstraZeneca and Sanofi, and the FDA demonstrated that nirsevimab appears to be safe and effective.
According to AstraZeneca's analysis, most RSV hospitalizations could be prevented with use of this drug.
In two clinical trials, involving nearly 3,000 babies, a single shot of the monoclonal antibody reduced the risks of an RSV case that required medical attention by 70-75%, and lowered the risks of hospitalization by 60-80%. High levels of the antibody persisted for at least five months. Side effects, including rashes and fevers, were uncommon and generally mild.
"This is a pathogen that has a substantial impact on the lives of young children, causing significant morbidity and mortality" and limits the ability of children who are sick with other illnesses to get medical care, says Dr. Steven Krug, a pediatric emergency physician and professor at the Northwestern University Feinberg School of Medicine.
Nirsevimab's approval broadens the protection available for babies. Prior to this approval the only existing preventive drug was a monoclonal antibody shot called palivizumab which requires monthly administration and is reserved for babies at high medical risk.
Dr. Marcus Plescia, chief medical officer for the Association of State and Territorial Health Officers, says it may take awhile for parents to warm up to the new drug. "It's recommended very soon after birth," he says. "A lot of parents are a little bit cautious about wanting to give really young children things. So it may take a little bit of time to really build confidence in the monoclonal antibody."
Authorities in the EU approved the antibody last fall, and it is currently being considered for use in several Asian countries.
This antibody shot is one of several new drugs and vaccines in development to protect babies and the elderly from RSV. The FDA is expected to issue a decision on an RSV vaccine to protect newborns that is given to pregnant mothers by late August.
This story has been updated. It originally ran June 8.
veryGood! (93)
Related
- Charges tied to China weigh on GM in Q4, but profit and revenue top expectations
- Here's Your First Look at The White Lotus Season 3 With Blackpink’s Lisa and More Stars
- Taking stock of bonds: Does the 60/40 rule still have a role in retirement savings?
- Kelly Rowland and Nelly Reunite for Iconic Performance of Dilemma 2 Decades Later
- Who's hosting 'Saturday Night Live' tonight? Musical guest, how to watch Dec. 14 episode
- Deebo Samuel explains 'out of character' sideline altercation with 49ers long snapper, kicker
- Suspect arrested after deadly Tuskegee University homecoming shooting
- AIT Community Introduce
- New data highlights 'achievement gap' for students in the US
- Brian Kelly asks question we're all wondering after Alabama whips LSU, but how to answer?
Ranking
- 'We're reborn!' Gazans express joy at returning home to north
- NASCAR Hall of Fame driver Bobby Allison dies at 86
- Question of a lifetime: Families prepare to confront 9/11 masterminds
- NFL playoff picture Week 10: Lions stay out in front of loaded NFC field
- Global Warming Set the Stage for Los Angeles Fires
- Republican David Schweikert wins reelection in affluent Arizona congressional district
- Chiefs block last-second field goal to save unbeaten record, beat Broncos
- The Army’s answer to a lack of recruits is a prep course to boost low scores. It’s working
Recommendation
California DMV apologizes for license plate that some say mocks Oct. 7 attack on Israel
Climate Advocacy Groups Say They’re Ready for Trump 2.0
‘I got my life back.’ Veterans with PTSD making progress thanks to service dog program
Reds honor Pete Rose with a 14-hour visitation at Great American Ball Park
Person accused of accosting Rep. Nancy Mace at Capitol pleads not guilty to assault charge
Are Ciara Ready and Russell Wilson Ready For Another Baby? She Says…
The Cowboys, claiming to be 'all in' prior to Dak Prescott's injury, are in a rare spot: Irrelevance
Taylor Swift Politely Corrects Security’s Etiquette at Travis Kelce’s Chiefs Game